Cambridge, Massachusetts, United States · Remote OK
$240k–$275k/yr
Who We Are If you're passionate about gene therapy and its ability to enhance the lives of patients, then Beacon is a great team to join. We're a diverse, multi-national team of talented people all working together at ou…
Skills: CMC Technical Operations, 3PL/4PL Supply Chain, Gene Therapy, Viral Vector Production, Late-stage Submission
Cambridge, Massachusetts, United States • Remote OK
Sign up with Clera and we'll reach out the moment a role actually fits you — no more spraying applications into the void.
Lead CMC execution for late-stage gene therapy programs with a focus on establishing commercial supply chains via 3PL and 4PL partners. Manage critical external partners and provide cross-functional technical leadership to ensure launch readiness and program adherence.
Requires extensive experience in late-stage biopharma submissions and launch, specifically building 3PL/4PL supply chains for gene therapies. Must possess strong CMC fundamentals (CPPs, CQAs) and a proven ability to influence senior multinational stakeholders.
If you're passionate about gene therapy and its ability to enhance the lives of patients, then Beacon is a great team to join. We're a diverse, multi-national team of talented people all working together at our sites in the US and the UK, or as a remote contributor. Everyone here, whatever their role or location, plays a genuine part in bringing our treatments to patients. Everyone has a voice, and every contribution makes a difference.
As Executive Director, CMC Technical Operation, you will strengthen CMC execution for late-stage gene therapy programs, particularly for market-facing supply chain activities including 3PL and 4PL, ensure CMC programme activities land on schedule, issues are driven to closure, and stakeholders remain aligned across internal teams and external partners.
- Drive the selection, establishment, and build-out of 3PL and 4PL partners to ensure a robust commercial supply chain for our lead product
- Ensure management of critical external partners at a senior level across analytics, DS, and DP manufacturing
- Develop and maintain CMC guidance and decision frameworks; Support Area Leads/ senior CMC leaders (direct/indirect) to actively resolve programme issues (internal or external)
- Ensure proactive communications of progress vs plan with internal and external stakeholders
- Provide cross-functional technical leadership spanning viral vector production, analytics, quality, regulatory, and supply
- Support and guide late-stage submission and launch readiness, translating strategy into executable CMC plans
- Navigate complex technical and organizational challenges with clear, influential communication
- Multi-disciplinary late-stage submission/launch experience in biopharma, preferably gene therapies, with a supply chain focus
- Strong CMC fundamentals (CQAs, CPPs, etc) and strategic program optimization mindset
- Demonstrated success influencing senior, multinational stakeholders
- Clear, defined, and direct experience of building-out 3PL and 4PL supply chains for biopharmaceuticals AND a solid understanding of biopharmaceutical technical fundamentals (CPPs, CQAs) combined with a senior profile capable of managing senior stakeholders (internal, external) are key/must-have requirements for this role. If you are ready to broaden your CMC leadership scope toward enterprise-level ownership, we encourage you to apply.
You'll move between focused working sessions, programme health-checks, and senior-level touchpoints-aligning internal functions with CDMOs, packaging and logistics partners, and other external stakeholders, while constantly scanning for risks and ensuring programme adherence. As issues surface, you'll facilitate rapid root-cause discussions, confirm decision paths, and keep communications crisp for executive audiences. You'll also carve out time to review program status and ensure teams have the clarity and support needed to maintain momentum. Working fully remote on an Eastern schedule (Mon–Fri, 8am–5pm), you'll balance deep technical context with pragmatic delivery and stakeholder management, while keeping late-stage activities progressing without unnecessary friction.
Beacon Therapeutics (USA) Inc offers a comprehensive benefits package designed to support long-term health and financial stability, including Medical, Dental, and Vision coverage; 401(k); Life Insurance; Health Savings Account (HSA) and Flexible Spending Account (FSA) options; Employer paid STD & LTD benefits; Paid Time Off; and Employee Discounts. This role is offered with a Competitive Salary range of $240,000–$275,000.
Transforming Vision, Transforming Lives
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The Company is harnessing the transformative power of gene therapy to deliver the most meaningful outcomes for severe ocular diseases. Beacon’s pipeline currently targets devastating blinding retinal diseases such as X-linked retinitis pigmentosa (XLRP) and geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Beacon Therapeutics’ investors include Advent Life Sciences, Forbion, Life Sciences at Goldman Sachs Alternatives, Oxford Science Enterprises, Retinal Degeneration Fund, Syncona Limited, and TCGX, among others. Learn more about Beacon Therapeutics at beacontx.com and follow on LinkedIn for more updates.
Offices: 188 York Way, Kings Cross, Rolling Stock Yard, 2nd floor,, London, N7 9AS, GB · 100 Cambridgepark Dr, Suite 2200, Cambridge, Massachusetts 02140, US
Transforming Vision, Transforming Lives
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The Company is harnessing the transformative power of gene therapy to deliver the most meaningful outcomes for severe ocular diseases. Beacon’s pipeline currently targets devastating blinding retinal diseases such as X-linked retinitis pigmentosa (XLRP) and geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Beacon Therapeutics’ investors include Advent Life Sciences, Forbion, Life Sciences at Goldman Sachs Alternatives, Oxford Science Enterprises, Retinal Degeneration Fund, Syncona Limited, and TCGX, among others. Learn more about Beacon Therapeutics at beacontx.com and follow on LinkedIn for more updates.
Offices: 188 York Way, Kings Cross, Rolling Stock Yard, 2nd floor,, London, N7 9AS, GB · 100 Cambridgepark Dr, Suite 2200, Cambridge, Massachusetts 02140, US
